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Synovial injury and healing are complex processes including catabolic effects by proinflammatory cytokines and anabolic processes
by anti-inflammatory mediators. Here we examined the expression of pro- versus anti-inflammatory mediators in synovium of
patients with diagnostic arthroscopy (control), joint trauma (JT), osteoarthritis (OA), and rheumatoid arthritis (RA). Synovial
samples from these patients were subjected to RT-PCR and double immunofluorescence confocal microscopy of pro- and anti-
inflammatory mediators as well as immune cell markers. Interestingly, pro- and anti-inflammatory mediators were expressed
predominantly in granulocytes in patients with JT and in macrophages, lymphocytes, and plasma cells in patients with OA and
RA. Interestingly, parallel to the severity of inflammation, proinflammatory mediators IL-1𝛽, TNF-𝛼, and 5-LOX specific mRNA
as well as immunoreactive (IR) cells were significantly more abundant in patients with RA and JT than in those with OA. However,
anti-inflammatory mediators 15-LOX, FPR2, and IL-10 specific mRNA as well as IR cells were significantly more abundant in
patients with OA than in those with JT and RA. These findings show that upregulation of proinflammatory mediators contributes
to the predominantly catabolic inflammatory process in JT and RA synovium, whereas upregulation of anabolic anti-inflammatory
mediators counteracts inflammation resulting in the inferior inflammatory process in OA synovium.
1. Introduction
In inflammatory joint diseases such as joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA), the
inflammatory process within synovial tissue leads to tissue
destruction and fibrosis with varying degrees of severity [1–
3]. The degree of severity depends on processes that are tak-
ing place inside the synovium including catabolic effects
by proinflammatory cytokines concomitant with anabolic
processes by anti-inflammatory mediators [4]. The most
important group controlling the state of disease seems to
be inflammatory cytokines including interleukin-1 𝛽 (IL-1𝛽)
and tumor necrosis factor-alpha (TNF-𝛼). Tumor necrosis
factor-alpha (TNF-𝛼), togetherwith IL-1𝛽, is considered a key
inflammatory cytokine involved in the pathophysiological
processes occurring in the course of chronic disease of human
synovium. Also, the lipoxygenase isoform of 5-lipoxygenase
(5-LOX) is reported to be overexpressed in synovial tissue of
patients suffering from rheumatoid arthritis and osteoarthri-
tis.The 5-LOX is involved in the progress of inflammation [5].
The other group opposing these proinflammatory effects
in synovial tissue is formed by anti-inflammatory med-
iators such as 15-LOX, formyl peptide receptor (FPR2), and
IL-10 [6, 7]. Previous studies demonstrated that 15-LOX
Hindawi
Mediators of Inﬂammation
Volume 2017, Article ID 9243736, 11 pages
https://doi.org/10.1155/2017/9243736
2 Mediators of Inflammation
metabolites have potent anti-inflammatory actions on rheu-
matoid inflammation [8]. FPR2, also known as the lipoxin
A4 receptor (ALX), belongs to the Gi-protein coupled
receptor (GiPCR) family and is activated by lipoxin A4,
AnnexinA1, andAnnexinA1-derived peptides or by the acute
phase reactant serum amyloid A resulting in potent anti-
inflammatory effects [9, 10]. Similarly, IL-10 inhibits chemo-
kine and cytokine production from macrophages and den-
dritic cells that leads to a limitation of the acute and chronic
inflammation [11–13].The exact cell types anddisease-specific
differences in the occurrence of pro- versus anti-inflam-
matory mediators within human synovium of patients with
JT, OA, and RA have not been examined so far.
Therefore, we investigated the expression of proinflam-
matory (IL-1𝛽, TNF-𝛼, and 5-LOX) and anti-inflammatory
(15-LOX, FPR2, and IL-10) mediators in synovium of patients
with JT, OA, and RA.We assessed the differences in the num-
ber and types of cells expressing proinflammatory and anti-
inflammatory mediators by the use of different markers
for synovial fibroblasts (P4HB), macrophages/monocytes
(CD68), granulocytes (CD15), T lymphocytes (CD3), and
plasma cells Ab-1. This study may provide conclusive evi-
dence of a disease-specific profile of proinflammatory versus
anti-inflammatory mediators as well as cell types involved
that may contribute to a better understanding of these oppos-
ing mechanisms and to potential targets for the modulation
of these processes.
2. Materials and Methods
2.1. Patients and Synovial Sample Collection. Patients were
recruited in three different hospitals: DRK Clinic Westend
Berlin, Landeskrankenhaus Klagenfurt, and the University
Hospital Regensburg. IRB approval was obtained from all
three locations and patients gave their written consent to the
participation in this study after they were informed of its pur-
pose (EA). Patients were included when they were scheduled
for surgery and had a diagnosis of osteoarthritis, rheumatoid
arthritis (according to the criteria of the American College
of Rheumatology and to the clinical and radiological criteria
of OA) [14, 15], or joint trauma. Patients undergoing a
diagnostic arthroscopy were chosen as a control. During
surgery, synovial tissues were taken from patients of all four
groups and stored at −80∘C.
2.2. RT-PCR. Frozen synovial tissue samples were homog-
enized, and then the total RNA was isolated using the Kit
Qiazol Lysis Reagent (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. For cDNA synthesis, 500 ng
total RNA was isolated by NanoDrop (Peqlab). Then, 500 ng
total RNA was converted to cDNA at 42∘C for 1 h using
Omniscript RTKit (Qiagen, Hilden, Germany) by incubation
with 0.5mM dNTP, 1𝜇M Random Primer, 10 units RNase
Inhibitor, and 4 units Omnisript reverse Transcriptase. The
obtained DNA was stored at −20∘C. The following specific
primers for IL-1𝛽, TNF-𝛼, 5-LOX, 15-LOX, FPR2, IL-10,
and 18s were used (see primers’ information in Supple-
mental Table 1 (see Supplementary Material available online
at https://doi.org/10.1155/2017/9243736). Finally, TaqMan
qRT-PCR was performed using a SYBRGreen kit according
to the manufacturer’s instructions (Applied Biosystems).
Amplification was executed with 40 cycles, each consisting of
15 s at 95∘C and of 30 s at 60∘C. To detect fluorescence specific
products for each primer pair, the reaction was carried out
at a temperature just below the specific melting temperature
(Tm). For statistical analysis, experiments were performed in
triplicate in order to determine TNF-𝛼, IL1𝛽, 5-LOX, 15-LOX,
and FPR2 mRNA by the delta-delta CT method as described
previously [16].
2.3. Tissue Preparation and Histological Evaluation. Intact
synovial tissue was fixed in 4% (w/v) paraformaldehyde in
0.16M phosphate buffer solution (PBS) (pH 7.4) for 4 hours
and then cryoprotected overnight at 4∘C in PBS containing
10% sucrose. The tissue was then embedded in tissue-Tek
compound (OCT, Miles Inc. Elkhart, Indiana) and frozen.
For histology, 8 𝜇m sections were cut by using a Cryostat
(Thermo Fisher, Dreieich, Germany) and were mounted
onto gelatin-coated slides. Histological evaluation of intact
synovial tissue was performed as previously described [17],
identifying the components of lining cell layers, sublin-
ing cells. Cell density was determined in 3 fields in each
section of at least 4 different tissue samples from each
group (hematoxylin-eosin stained) by counting all stained
cell nuclei within 3 randomly selected high-power fields
of view per section (400x magnification). The lining-layer
thickness was determined from at least three sections and
analyzed by averaging the number of cells of three fields
per section (400x magnification). The number of B cells,
macrophages, fibroblast-like cells, granulocytes, and lympho-
cytes were evaluated in cryosections stained with antibodies
against human plasma cells Ab-1, macrophages (CD68),
fibroblasts (P4HB), granulocytes (CD15), and lymphocytes
(CD3), respectively. The number of stained structures was
averaged from 12 randomly selected high-power fields (400x
magnification).The number of high-power fields was derived
from a histological study by Bresnihan et al., (1998) [18].
2.4. Single and Double Immunofluorescence Staining Proce-
dures. Immunofluorescence staining was processed as des-
cribed previously [19]. The mounted slide tissue sections
were incubated overnight at 4∘C with the following pri-
mary antibodies (see antibodies’ information in supplemental
Table 1): single immunofluorescence staining was applied
in the following way: (1) anti-IL-1𝛽, (2) anti-TNF-𝛼, (3)
anti-5-LOX, (4) anti-15-LOX, (5) anti-FPR2, and (6) anti-
IL-10, respectively, in each group (Control, JT, OA, and
RA). Double immunofluorescence staining was performed
in RA samples in the following way: (1) anti-TNF-𝛼/anti-IL-
1𝛽, (2) anti-5-LOX/anti-FPR2, (3) anti-15-LOX/anti-5-LOX,
and (4) anti-IL-10/anti-FPR2; in OA samples: (1) anti-5-LOX/
anti-FPR2, (2) anti-TNF-𝛼/anti-IL1𝛽, (3) anti-15-LOX/anti-
5-LOX, and (4) anti-IL-10/anti-FPR2; in JT samples: (1)
anti-TNF-𝛼/anti-IL1𝛽, (2) anti-5-LOX/anti-FPR2, (3) anti-15-
LOX/anti-5-LOX, (4) anti-IL-10/anti-TNF-𝛼, and (5) anti-
IL-10/anti-FPR2. Antisera specific for certain immune cell
types (anti-CD15, anti-CD68, anti-P4HB, anti-CD3, and anti-
Ab-1) were applied together with anti-TNF-𝛼, anti-IL1𝛽,
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Table 1: Clinical and histological characteristics of patients with joint trauma, osteoarthritis, and rheumatoid arthritis.
Patients Control JT OA RA
(𝑛 = 5) (𝑛 = 9) (𝑛 = 11) (𝑛 = 10)
Age (years) 65 (±16,8) 48 (±17) 72 (±6) 64.9 (±17)
Sex (F/M) 1/4 9/6 5/2 6/4
Disease duration:
≤1 year 5/5 4/9 2/11 —
>1 year — 5/9 9/11 10/10
Drugs; NSAIDs: (Diclofenac, Ibuprofen, Profenid, Paracetamol, Dipyrone) 5/5 8/9 8/11 8/10
Etoricoxib NA 1/9 3/11 1/10
Prednisolone (Dexamethasone) NA NA NA 7/10
Lining-layer thickness (cell-layers) 1 (1; 2) 2 (1; 3) 3 (3; 4) 4 (3; 5)
Overall cellularity (cells/mm2) 47 (44; 49) 124 (97; 138) 269 (220; 285) 387 (358; 474)



































































Control RAJT 5-LOX 5-LOX 5-LOX5-LOX OA
(c)
Figure 1: Detection of 5-LOX mRNA (a) and number of 5-LOX-IR cells (b and c) in patients with joint trauma (JT), osteoarthritis (OA),
and rheumatoid arthritis (RA). (a) Quantification of 5-LOX mRNA using TaqMan qRT-PCR shows that 5-LOX mRNA was significantly
higher in RA compared to JT, OA, and control synovium (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). (b) Quantitative analysis of
immunofluorescence microscopy for 5-LOX-IR cells. ∗Relative to control, #relative to other groups (𝑃 < 0.05, one-way ANOVA followed by
Tukey’s test). (c) 5-LOX-IR cells are more abundant in RA synovium than in JT, OA, and control synovium. Bar = 20𝜇m.
anti-5-LOX, anti-15-LOX, anti-FPR2, or IL-10 within each
group. Then, the slides were washed in PBS and for 2 hours
incubated with Alexa Fluor 488 donkey anti-rabbit antibody
(Vector Laboratories) or with Alexa Fluor 594 donkey anti-
goat or with Alexa Fluor 594 donkey anti-mouse (Invitrogen,
Germany) (in single staining). For double staining, slides
were incubated with Alexa Fluor 488 donkey anti-rabbit
antibody combined with Alexa Fluor 594 donkey anti-goat,
Alexa Fluor 594 donkey anti-mouse combined with Alexa
Fluor 594 donkey anti-goat, or Alexa Fluor 594 donkey
anti-mouse combined with Alexa Fluor 488 donkey anti-
rabbit. Finally, the tissues were washed in PBS, and nuclei
were stained with DAPI (4󸀠,6-diamidino-2-phenylindole)
and then mounted in Vectashield (Vector Laboratories) and
imaged on a confocal laser scanning microscope, LSM510, as
described previously [19]. Then, the photographs were taken
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Control OA FPR2RAFPR2JTFPR2 FPR2RA
(c)
Figure 2: Detection of FPR2 mRNA (a) and number of FPR2-IR cells (b and c) in patients with joint trauma (JT), osteoarthritis (OA), and
rheumatoid arthritis (RA). Quantification of FPR2 mRNA (a) and immunofluorescence positive cells (b) shows that FPR2 expression was
more prominent in OA compared to RA, JT, OA. ∗Relative to control, #relative to other groups (𝑃 < 0.05, one-way ANOVA followed by
Tukey’s test). Data are shown as means ± SEM. (c) 5-LOX-IR cells are more abundant in RA synovium than in JT, OA, and control synovium.
SEM. Bar = 20 𝜇m.
by a confocal microscope (633 nm; Carl Zeiss, Go¨ttingen,
Germany) as described in our previous study [20]. To demon-
strate specificity of staining, the following controls were
included: omission of the primary antisera or the secondary
antibodies, as described in our previous studies [19].
2.5. Quantification of Immunostaining. Themethod for quan-
tification of the number of immunoreactive cells has
been described previously [19]. Immunoreactive cells were
counted using only intact tissue exhibiting optimal morphol-
ogy to avoid misleading results. The numbers of proinflam-
matory (IL-1𝛽, TNF-𝛼, and 5-LOX,) and anti-inflammatory
(15-LOX, FPR2, and IL-10) immunoreactive cells were
counted by a blinded experimenter in three sections per
patient. The value of stained proinflammatory and anti-
inflammatory mediators was determined by the formula:
stained cells/stained cells of control× 100. Datawere obtained
from three sections per patient from each group: Control
(𝑛 = 5), JT (𝑛 = 9), OA (𝑛 = 11), and RA (𝑛 = 10).
2.6. Statistical Analysis. Data are represented as means ±
SEM. Sample comparisonsweremade using one-way analysis
of variance followed by Tukey test in the case of normally dis-
tributed data and Kruskal–Wallis analysis of variance on
ranks followed by Dunn’s test in the case of data not
distributed normally. Differences were considered significant
if 𝑃 < 0.05. All tests were performed using Sigma Plot 13.0
statistical software.
3. Results
3.1. Patient Recruitment, Demographics, and Synovial Signs
of Inflammation. For this study, a total of 42 patients were
screened. Seven patients were excluded during the workup,
because tissue samples could not be identified histologically
as synovial tissue. The remaining patients were distributed
according to their clinical diagnosis among the following
groups: Control (𝑛 = 5), JT (𝑛 = 9), OA (𝑛 = 11), and RA
(𝑛 = 10).
Patients’ demographics such as patient’s age, gender,
disease duration, and medications are shown in Table 1.
Light microscopic evaluation of patients’ synovial tissues for
lining-layer thickness, overall cellularity, and vascularity was
significantly different for patients with RAbut not for patients
of the other groups compared to control (𝑃 < 0.05) (Table 1).
Overall synovial cellularity was further characterized in
greater detail by immunofluorescent microscopy showing
different types of immune cells andfibroblasts. Synovial tissue
of patients suffering from OA and RA showed significantly
more regional immune cells and fibroblasts than control
Mediators of Inflammation 5
































































Control JT RA 15-LOX15-LOX15-LOX15-LOX OA
(c)
Figure 3: Detection of 15-LOXmRNA (a) and number of 15-LOX-IR cells (b and c) in patients with joint trauma (JT), osteoarthritis (OA), and
rheumatoid arthritis (RA). (a) Quantification of 15-LOXmRNA shows that 5-LOXmRNAwas significantly higher in OA and JT compared to
RA and control synovium (𝑃 < 0.05, one-wayANOVA followed by Tukey’s test). (b)Quantitative analysis of immunofluorescencemicroscopy
for 15-LOX-IR cells. ∗Relative to control, #relative to other groups (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). Data are shown as
means ± SEM. (c) 5-LOX-IR cells are more abundant in RA synovium than in JT, OA, and control synovium. Bar = 20 𝜇m.
patients and patients with JT (𝑃 < 0.05). While in patients
with JT synovial granulocytes and macrophages were most
prominent, in patients with OA fibroblasts and macrophages
were the most prominent, and in patients with RA plasma
cells, fibroblasts, and macrophages were the most prominent
(𝑃 < 0.05) (Supplemental Figure 1).
3.2. Expression of Synovial Proinflammatory Mediators IL-1𝛽,
TNF-𝛼, and 5-LOX. Quantitative RT-PCR analysis demon-
strated a significant increase in IL-1𝛽 and TNF-𝛼 specific
mRNA in synovial tissue of JT, OA, and RA patients in con-
trast to controls. In addition, they were more prominent in
JT and RA than in OA patients (Supplemental Figures 2 and
3). Consistently, immunofluorescence confocal microscopy
of synovial tissue demonstrated IL-1𝛽 and TNF-𝛼 expression
in layers of synovial lining and sublining cells. Importantly,
the number of IL-1𝛽- and TNF-𝛼-IR cells was significantly
higher in patients with JT, OA, and RA compared to controls
(𝑃 < 0.05) and was more pronounced in JT and RA than
OApatients (Supplemental Figures 2 and 3). Quantitative RT-
PCR analysis of 5-LOX specific mRNA revealed a significant
increase in synovial tissues of RA patients, while immunoflu-
orescence confocal microscopy showed a significant increase
of 5-LOX-IR cells in synovial tissues of JT, OA, and RA
patients compared to controls which was more prominent in
RA patients (𝑃 < 0.05, Figure 1).
3.3. Expression of Synovial Anti-Inflammatory Mediators,
FPR2, 15-LOX, and IL-10. FPR2 specific mRNA showed a
significant increase in synovial tissues of JT, OA, and RA
patients compared to controls which was most prominent
in OA patients (Figure 2), while 15-LOX mRNA was shown
only in JT and OA (Figure 3). However, IL-10 mRNA was
prominent only in OA and RA patients (Figure 4). Consist-
ent with these findings, the number of FPR2-IR cells was
significantly higher in JT, OA, and RA patients than that of
control synovium (Figure 2). However, the number of 15-
LOX-IR cells was more prominent in JT and OA than that
of RA patients and control synovium (Figure 3), while the
number of IL-10-IR cells was higher in RA and OA patients
than that of JT and control synovium (Figure 4).
Double immunofluorescence confocal microscopy
showed that FPR2 was expressed in CD68-IR macrophages
and P4HB-IR fibroblasts in JT, OA, and RA as well as in Ab-1
plasma cells in RA (Supplemental Figure 4). 15-LOX-IR cells
were characterized as CD68-IR macrophages and P4HB-IR
fibroblasts in OA (Supplemental Figure 5). IL-10-IR cells
were mainly CD68-IR macrophages and P4HB-IR fibro-
6 Mediators of Inflammation































































Control IL-10 IL-10JT IL-10OA IL10RA
(c)
Figure 4: Detection of IL10 mRNA (a) and number of IL10-IR cells (b and c) in patients with joint trauma (JT), osteoarthritis (OA), and
rheumatoid arthritis (RA). (a) Quantification of IL10 mRNA shows that IL10 mRNA was significantly higher in RA and OA compared to JT
and control synovium (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). (b) Quantitative analysis of immunofluorescence microscopy
for IL10-IR cells. ∗Relative to control, #relative to other groups (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). Data are shown as
means ± SEM. (c) 5-LOX-IR cells are more abundant in RA synovium than in JT, OA, and control synovium. Bar = 20 𝜇m.
blasts in OA and in RA as well as in Ab-1 plasma cells in RA
(Supplemental Figure 6).
3.4. Inflammatory Mediator Profile in JT, OA, and RA. Direct
comparison of the mRNA expression profile of pro- versus
anti-inflammatory mediators in synovial tissues revealed
that cells expressing the proinflammatory mediators IL-1𝛽,
TNF-𝛼, and 5-LOX were elevated approximately 4- to 8-
fold compared to controls in JT (Figure 5), whereas they
were upregulated only 2- to 4-fold in OA (Figure 6). At the
same time, the anti-inflammatory mediators 15-LOX, FPR2,
and IL-10 were found to be elevated approximately 2- to
6-fold in JT (Figure 5), whereas in OA they were elevated
approximately 5- to 7-fold (Figure 6). In contrast, in synovial
tissue of RA patients, the proinflammatory mediators IL-1𝛽,
TNF-𝛼, and 5-LOX were elevated approximately 5- to 13-
fold compared to controls, whereas the anti-inflammatory
mediators 15-LOX, FPR2, and IL-10were upregulated approx-
imately 3- to 7-fold (Figure 7).
4. Discussion
We found the highest amount of synovial lining cells, vascu-
larity, and infiltrating immune cells in patients with RA com-
pared to those with JT and OA. Pro- and anti-inflammatory
mediators were expressed predominantly in granulocytes
and macrophages in patients with JT and in macrophages,
fibroblasts, and plasma cells in those with OA and RA.
Overall, proinflammatory IL-1𝛽, TNF-𝛼, and 5-LOX specific
mRNA as well as immunoreactive cells were significantly
more abundant in patients with RA and JT than in those
with OA. In contrast, anti-inflammatory 15-LOX, FPR2, and
IL-10 specific mRNA as well as immunoreactive cells were
significantlymore abundant in patientswithOA than in those
with JT and RA. These findings provide a morphological
evidence of imbalance within the so-called inflammatory fac-
tor network between catabolic proinflammatory and anabolic
anti-inflammatorymediators among JT,OA, andRApatients.
The lining layer of the synovial membrane contains
macrophage-like (type A cells) and fibroblast-like (type B
cells) cells [19, 21, 22]. Our double staining demonstrated that
most of the lining-layer cells containing proinflammatory
cytokines such as IL1𝛽, TNF-𝛼, and 5-LOX were positive
for CD68 (macrophages), CD15 (granulocytes), and P4HB
(fibroblast-like synoviocytes, type B) [19]. In the sublining
layers, we found different patterns of pro- versus anti-inflam-
matory mediators containing leukocyte subsets in patients
with JT, OA, and RA. Pro- and anti-inflammatory mediators
were expressed predominantly in granulocytes in patients
with JT and inmacrophages, lymphocytes, and plasma cells in


















































































Figure 5: Detection of mRNA (a) and the number of positive cells of inflammatory (IL-1𝛽, TNF-𝛼, and 5-LOX) versus anti-inflammatory (15-
LOX, FPR2, and IL-10) mediators (b and c) in patients with joint trauma (JT). (a) Quantification of mRNA of pro- versus anti-inflammatory
mediators shows that there is a balance between expressions of pro- versus anti-inflammatory mediators in JT synovium. (b) Quantitative
analysis of immunofluorescence microscopy of pro- versus anti-inflammatory mediators shows that the number of cells expressing anti-
inflammatory mediators was comparable with those containing proinflammatory mediators in JT synovium. Data are shown as means ±
SEM. ∗Relative to control (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). (c) Confocal microscopy of pro- (red fluorescence; (a), (b))
and anti-inflammatorymediators (green fluorescence; (c), (d)) double immunofluorescence (e–h) in JT synovium.Note that anti-inflammatory
mediator expression was comparable with those containing inflammatory mediators in JT synovium. Bar = 40𝜇m.
those with OA and RA.These results extend previous reports
of the expression of 5-LOX in macrophages, fibroblasts, and
neutrophils [5] and TNF-𝛼 in macrophages and monocytes
[23] within RA synovium.
Importantly, our results showed that IL-1𝛽 and TNF-𝛼
and 5-LOX specific mRNA as well as cells expressing these
mediators within synovial tissue were more prominent in JT
and RA compared to OA patients. These findings are consis-
tent with high levels of 5-LOX reported to be present in RA
synoviumandmostly expressed inmacrophages, neutrophils,
andmast cells of the sublining layer [5]. Also, our results are in
agreement with the previous study by Park and Pillinger [24],
suggesting that the inflammatory mediators such as TNF-
𝛼, IL-1𝛽, and 5-LOX play a key role in driving the inflam-
mation and synovial cell proliferation in RA associated joint
destruction. Taken together, these results suggest that there
is an association between the expression of proinflammatory
mediators such as TNF-𝛼, IL-1𝛽, and 5-LOX and the severity
of inflammation among patients with JT, OA, and RA [19].
On the other hand, the present results showed that
the anti-inflammatory cytokines 15-LOX, FPR2, and IL-10
specific mRNA as well as immunoreactive cells were more
abundant in patients with OA than in those with JT and RA.
The present results extend the previous reports of 15-LOX
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Figure 6: Detection of mRNA (a) and the number of positive cells of pro- (IL-1𝛽, TNF-𝛼, and 5-LOX) versus anti-inflammatory (15-
LOX, FPR2, and IL-10) mediators (b and c) in patients with osteoarthritis (OA). Quantification of mRNA of pro- versus anti-inflammatory
mediators shows that anti-inflammatory mediator expression was more prominent than inflammatory mediators in OA synovium. ∗Relative
to control (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). (b) Quantitative analysis of immunofluorescentmicroscopy pro- versus anti-
inflammatory mediators shows that the number of cells expressing anti-inflammatory mediators was more prominent than those containing
proinflammatory mediators in OA synovium; the asterisks denote significant differences (𝑃 < 0.05, one-way ANOVA followed by Dunn’s
test). Data are shown as means ± SEM. (c) Confocal microscopy of pro- (red fluorescence; (A) and (B)) and anti-inflammatory mediators
(green fluorescence; (C) and (D)) double immunofluorescence in OA synovium. Note that anti-inflammatory mediator expression was more
prominent than proinflammatory mediators in OA synovium. Bar = 40 𝜇m.
expression in humans [5] that did not differentiate the syn-
ovial cell types. IL-10 is a potent immunoregulatory cytokine
and plays a role in preventing exaggerated inflammatory and
immune responses and thus protects the host from immune-
mediated damage [25]. Moreover, IL-10 is a good candidate
transgene to suppress arthritis using disease-regulated pro-
moters. Also, IL-10 is a broad spectrum anti-inflammatory
cytokine and is produced by different immune cells, like Th1
and Th2 cells, B cells, monocytes, and macrophages [11–13].
Inhibition of several proinflammatory cytokines has been
reported; effects were seen for interleukin-1 (IL-1) and TNF-𝛼
[26, 27]. Recently, Vermeij et al. [28] showed that treatment of
an acute joint inflammation with local IL-10 overexpression
under the control of disease-regulated promoters inhibited
arthritis progression. Consistently, Roybal et al. [29] showed
that the early gestational gene transfer of IL-10 by systemic
administration of lentiviral vector can prevent arthritis in
a murine model. Taken together, these findings are consis-
tent with the notion that the upregulated proinflammatory
mediators support the inflammatory process in JT and RA
synovium in contrast to the upregulated anti-inflammatory
mediators probably responsible for a counterbalance and,
therefore, lower inflammatory process in OA synovium.
A potential limitation of this study, however, is that the























































































Figure 7: Detection of mRNA (a) and the number of positive cells of pro- (IL-1𝛽, TNF-𝛼, and 5-LOX) versus anti-inflammatory (15-LOX,
FPR2, and IL-10) mediators (b and c) in patients with rheumatoid arthritis (RA). Quantification of mRNA of pro- versus anti-inflammatory
mediators shows that proinflammatory mediators expressions were more prominent than anti-inflammatory mediators in RA synovium.
∗Relative to control (𝑃 < 0.05, one-way ANOVA followed by Tukey’s test). (b) Quantitative analysis of immunofluorescence microscopy pro-
versus anti-inflammatory mediators shows that the number of cells expressing proinflammatory mediator expression was more prominent
than those containing anti-inflammatory mediators in OA synovium; the asterisks denote significant differences (𝑃 < 0.05, one-way ANOVA
followed by Dunn’s test). Data are shown as means ± SEM. (c) Confocal microscopy of pro- (red fluorescence; (A) and (B)) and anti-
inflammatorymediators (green fluorescence; (C) and (D)) double immunofluorescence in RA synovium. Note that proinflammatorymediator
expression was more prominent than anti-inflammatory mediators in RA synovium. Bar = 40 𝜇m.
observed differences, at least in part, may be also due to
apparent differences in age and disease duration of patients
influencing the disease-specific pro- and anti-inflammatory
balance (see Table 1).
In summary, we found that the upregulation of proin-
flammatory mediators mediates the predominantly catabolic
inflammatory process in JT and RA synovium, whereas the
upregulation of anabolic anti-inflammatory mediators may
counteract inflammation and be responsible for the infe-
rior inflammatory process in OA synovium. These findings
provide a morphological evidence of imbalance within the
so-called inflammatory factor network between catabolic
proinflammatory and anabolic anti-inflammatory cytokines
within each disease and among JT, OA, and RA patients.
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